

## Company Overview


T-NanoBio Therapeutics, Inc., a Delaware corporation, is an emerging biotechnology company developing an innovative therapeutic platform based on transformable peptide nanoparticles. The technology consists of bispecific peptides that self-assemble, targeting tumor cells and cytotoxic T-cells, which result in a potent anti-tumor response in multiple oncology indications. Our nano immuno-engager (“NIE”) platform can harness a patient’s own immune system against cancer, while our HER2+ platform will offer a new treatment paradigm for treating HER2+ tumors. The company has sufficient data to progress into pharma/tox studies within 12 months of funding, followed by an IND filing within 20 months. The Company is comprised of a very senior and seasoned team with expertise in science, clinical development, finance, business, commercialization, CMC and corporate development with over 120 years of combined experience.

## Platform Highlights

- Demonstrated conversion of ‘cold’ to ‘hot’ tumors in a syngeneic murine cancer model, creating the ideal clinical setting for immune checkpoint inhibitors.
- In combination with anti-PD-1 antibody, the therapy was able to cure lung and breast cancer bearing mice, resulting in 100% overall survival in mice.
- Induced immune memory response against future implantation of breast cancer cells.
- HER2+ targeted transformable nanoparticles as a monotherapy have demonstrated curing HER2+ breast cancer in mice.
- Exclusively licensing technology from the University of California Davis Cancer Center.


## How does the Nano Immuno-Engager (“NIE”) work in Cancer Immunotherapy?

### Transformable Nano Particles (NP)



Self Assembly


### NIE-NPs



IV Injection




- 1) NIE delivered to the tumor
- 2) NIE transformed to nanofibrils at the tumor cell membrane
- 3) Nanofibril network at the TME captures  $T_{eff}$  cells
- 4) Allows sustained release of an immunostimulant



# Our Technology Differentiation: Transformation of Nanoparticles into a Nanofibril Network

Creating a nanofibril network that binds to the cancer cells within the Tumor Micro-Environment that:

- Prolongs the retention of the nanoengager system
- Captures the immune cells
- Activates the immune system
- Spares the normal tissues and organs



## Pipeline: Advancing Transformable Peptide Nanoparticle Programs

Product	Indication	Discovery	IND-enabling	Clinical
<b>NIE</b>	NSCLC, Melanoma, Breast, HNSCC	▶		
<b>HER2+</b>	Solid HER2+ (Breast, Gastric)	▶		
<b>Combination (NIE and HER2+)</b>	Solid HER2+ Tumors	▶		

### Leadership

**Anthony E. Maida III, PhD**

Co-Founder, Chief Executive Officer

**Kit S. Lam, MD, PhD**

Co-Founder, Chair of Scientific Advisory Board

**Robert H. Pierce, MD**

Chief Medical Officer

### Scientific and Clinical Advisors

o Kit S. Lam, MD, PhD (Chair)

o David Gandara, MD   o Jose Lutzky, MD

o Jerome Galon, PhD   o Kim Margolin, MD

o Primo Lara, MD   o James Talmadge, PhD

### Board Members

o Anthony E. Maida III PhD (Chair)

o William Ashton

o Kit S. Lam, MD, PhD

o Bernice Welles, MD



**Investor & Company Contact:**  
[BD@T-NanoBio.com](mailto:BD@T-NanoBio.com)